-
With the acceleration of the reshuffle of the pharmaceutical market, a large number of pharmaceutical companies are accelerating their focus on the main business
Time of Update: 2022-09-09
Recently, Shandong Xinhua Medical Device Co. , Ltd. issued an announcement on the transfer of the equity of its subsidiary, Shanghai Chenwei Zhongde Hospital Management Co. , Ltd. It is worth mentioni
-
The innovative drug industry chain maintains a high prosperity, and these companies are recommended by institutions
Time of Update: 2022-09-09
. According to the company's recently released semi-annual performance report, Haoyuan Pharmaceutical's innovative drug field achieved a year-on-year increase of 66.
. According to the company's recently released semi-annual performance report, Haoyuan Pharmaceutical's innovative drug field achieved a year-on-year increase of 66.
-
Anyang City deepens the reform of DRG payment and win-win results for medical treatment, insurance and patients
Time of Update: 2022-09-09
(Contributed by the Propaganda Department of the Anyang Municipal CPC Committee, correspondent Xu Meimei, Hui Hailiang)hospitals Medical security is a major institutional arrangement to reduce the burden of medical treatment, improve people's livelihood and well-being, and maintain social harmony and stability.
-
These proprietary Chinese medicine products actively withdraw from the net, what happened?
Time of Update: 2022-09-09
In addition to Guizhou Province, since the beginning of this year, Gansu, Anhui, Shanxi and other places have issued documents canceling the qualification of drugs hanging on the network, including a large number of proprietary Chinese medicine products.
-
Based on the increased investment in innovative research and development, a large number of pharmaceutical companies have shown vitality and potential
Time of Update: 2022-09-09
Increase investment in innovation and research and development, pharmaceutical companies show vitality and potential (Source: Pharmaceutical Network) For example, Renfu Pharmaceutical recently said in the 2022 semi-annual report that in the first half of the year, Renfu Pharmaceutical achieved double growth in operating income and net profit, increasing by 8.
-
In the second half of the year, mergers and acquisitions of biopharmaceutical companies are expected to accelerate
Time of Update: 2022-09-09
In recent years, the enthusiasm for mergers and acquisitions of listed biopharmaceutical companies has been high .
In recent years, the enthusiasm for mergers and acquisitions of listed biopharmaceutical companies has been high .
-
State Food and Drug Administration: 20 batches of comfrey and other drugs produced by 9 enterprises such as Zhengzhou Ruilong Pharmaceutical do not meet the regulations
Time of Update: 2022-09-09
The State Drug Administration requires the relevant provincial drug supervision and administration departments to organize a case filing and investigation of the suspected illegal acts of the above-mentioned enterprises and units in accordance with the Drug Administration Law of the People's Republic of China, and to disclose the results of the investigation and handling in accordance with regulations.
-
Alarm bells ring again! Another person who sold inferior drugs was fined a huge amount of 750,000 yuan!
Time of Update: 2022-09-09
In July, the Shanghai Municipal Supervision Bureau issued an administrative penalty decision showing that a Pharmaceutical Company in Shanghai had violated the law in producing inferior drugs, and the Bureau confiscated 76,645,140 yuan of illegal gains, fined 1.
-
Great strides into the harvest season!
Time of Update: 2022-09-09
Both internal and external training, external strategic cooperation is getting better Internal cost reduction and efficiency increase to improve profitability CStone's semi-annual report also pointed out that CStone continued to develop and deepen its relationships with major strategic partners around the world, and to expand the commercialization of both marketed and late-stage drugs .
-
As small as "6 nails" to "checklist ledger"! Medical insurance flight inspection from the detailed strict "reverse inspection for two and a half years"!
Time of Update: 2022-09-09
On August 23, the 2022 National Medical Security Fund Flight Inspection Yunnan Kick-off Meeting was held in Kunming. The National Medical Insurance Flight Inspection Team, composed of the National Me
-
There is huge room for improvement in the innovative drug market, which will inject impetus into the growth of pharmaceutical companies entering the board
Time of Update: 2022-09-09
The semi-annual report also disclosed that the company's innovative drug revenue will account for 24% of the total this year, and it is expected to exceed the 10 billion yuan mark by 2023 .
-
Keyue Pharmaceuticals will report the latest preclinical data of its lead project KP104 at the 18th European Conference on Complement and Human Disease
Time of Update: 2022-09-09
Oral presentation at the congress on the favorable pharmacokinetic and pharmacodynamic properties of intravenous and subcutaneous administration of KP104 in relevant animal models, supporting further
-
Medical insurance flight inspection stationed in Yunnan on the first day of the inspection of the institution did not let go of any suspicious points
Time of Update: 2022-09-09
" ”Diseases and diseases While the two were discussing, a member of the collection group picked up a stack of materials and trotted to the long table of the finance group: "We found a problem and need the support of the financial comrades!" ” A clear division of labor and mutual cooperation is the know-how for flight inspection teams to work efficiently.
-
The pharmaceutical intermediates industry is undergoing a qualitative transformation and is expected to reach a market size of 227.8 billion
Time of Update: 2022-09-09
The company's 2022 semi-annual report shows that in the first half of the year, Tuoxin Pharmaceutical's nucleotides and nucleoside series products achieved revenue of about 115 million yuan and 0.
-
What can I eat to make up for qi and blood deficiency?
Time of Update: 2022-09-09
What kind of medicine to take for qi and blood deficiency to make up for the quick effect?The first is a reasonable diet.
-
The State Food and Drug Administration issued a catalogue of generic drug reference preparations (the 57th batch)
Time of Update: 2022-09-09
Annex: Generic Reference Formulations Catalogue (Fifty-seventh Batch) State Food and Drug Administration August 25, 2022 After the review and determination of the Expert Committee on the Consistency Evaluation of the Quality and Efficacy of Generic Drugs of the State Drug Administration, the Catalogue of Generic Drug Reference Preparations (The Fifty-seventh Batch) is hereby released.
-
The antidiabetic drug market ushered in potential stocks! GLP-1RA drugs are eye-catching
Time of Update: 2022-09-09
The industry said that with the gradual strengthening of clinical evidence, GLP-1RA drugs are expected to benefit more type 2 diabetes patients in China, and the market size is expected to further expand.
-
NMPA: Omeprazole enteric-coated tablets are converted to over-the-counter medications
Time of Update: 2022-09-09
List of varieties serial number Product name Specifications (Composition) classify remark Double-span declaration categories 1 Omeprazole enteric-coated tablets 10 mg Class A Double span Chemical drugs 1 category 2.
-
What is the correct way to eat Tongrentang Wuji Baifeng Wan?
Time of Update: 2022-09-09
Let's learn the correct way to eat Tongrentang Wuji Baifeng Pills, and see how to eat Tongren Wuji Baifeng Pills correctly!The efficacy and composition of Tongren Wuji Baifeng PillAs mentioned earlier, Tongren Wuji Baifeng Pill has the effect of nourishing qi and blood, and regulating liver and kidney.
-
With the continuous acceleration of the review of new drugs, 4 more drugs have been included in the proposed priority review varieties
Time of Update: 2022-09-09
Sanofi China's α of ive glucosidase for injection was approved by CDE on August 15 as a priority review variety for long-term enzyme replacement therapy in patients with Pompe disease (acidic α glucosidase [GAA] deficiency).
